文献速递肝病消化道肿瘤与早癌

Sirtuin 4缺失通过调控腺苷单磷酸激活蛋白激酶α/哺乳动物雷帕霉素靶蛋白轴促进小鼠肝细胞癌肿瘤发生

Sirtuin 4 Depletion Promotes Hepatocellular Carcinoma Tumorigenesis Through Regulating Adenosine-Monophosphate-Activated Protein Kinase Alpha/Mammalian Target of Rapamycin Axis in Mice.
PubMed 文献 · Hepatology · 2019-03-12

本研究在肝细胞癌细胞系及患者肝癌组织中观察到SIRT4低表达,且低肿瘤SIRT4水平与患者无病生存时间缩短相关。SIRT4缺失通过调节谷氨酰胺分解及AMP/LKB1轴使AMPKα失活,从而增强mTOR信号,促进肝癌细胞集落形成、迁移及球体形成,并促进移植瘤和基因敲除小鼠的肝脏肿瘤发展与肺转移;雷帕霉素阻断mTOR或抑制谷氨酰胺分解可消除SIRT4缺失细胞的肿瘤生成能力差异。

要点

  • 肝细胞癌细胞系和患者肝癌组织中SIRT4表达低,低肿瘤SIRT4水平与无病生存时间缩短相关。
  • SIRT4缺失通过AMP/LKB1轴使AMPKα失活、增强mTOR信号,促进肝癌细胞集落形成、迁移和球体形成。
  • 雷帕霉素阻断mTOR或抑制谷氨酰胺分解可消除SIRT4缺失肝癌细胞与对照细胞的肿瘤生成能力差异。

核心结论

  • SIRT4可能通过抑制谷氨酰胺代谢、提高ADP/AMP水平,经LKB1磷酸化AMPKα并阻断mTOR信号通路,从而在肝细胞癌中发挥肿瘤抑制功能。

研究设计与样本

  • 研究检测了肝细胞癌细胞系及患者肝癌组织中SIRT4的表达,并利用移植瘤和基因敲除小鼠模型观察SIRT4缺失对肝脏肿瘤发展和肺转移的影响。

主要发现

  • 肝细胞癌细胞系和患者肝癌组织中SIRT4表达低,低肿瘤SIRT4水平与患者无病生存时间缩短相关。
  • SIRT4缺失促进肝癌细胞集落形成和迁移、增强肝细胞癌球体形成,并促进移植瘤和基因敲除小鼠的肝脏肿瘤发展与肺转移。
  • SIRT4缺失通过调节谷氨酰胺分解及后续AMP/LKB1轴使AMPKα失活,从而增强mTOR信号。
  • 雷帕霉素阻断mTOR或抑制谷氨酰胺分解可消除SIRT4缺失肝癌细胞与对照细胞之间的肿瘤生成能力差异。
  • 抑制LKB1或二甲双胍提高AMP可逆转SIRT4缺失所致的高增殖表型。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sirtuin 4 (SIRT4) has been reported to play a vital role in the maintenance of glutamine catabolism and adenosine triphosphate (ATP) homeostasis, but its character in hepatocellular carcinomas (HCCs) remains obscure. In this study, we observed low expression of SIRT4 in both HCC cell lines and HCCs from patients. Decreased disease-free survival time is associated with low tumor levels of SIRT4 in patients. Deficiency of SIRT4 facilitated liver tumor development and lung metastasis in xenografts and knockout (KO) mice by promoting colony formation and migration of hepatoma cells and enhancing sphere formation of HCCs. Mechanistically, SIRT4 deletion augmented mammalian target of rapamycin (mTOR) signaling by inactivating adenosine-monophosphate (AMP)-activated protein kinase alpha (AMPKα) through regulation of glutamine catabolism and subsequent AM)/liver kinase B1 (LKB1) axis. Blockage of mTOR by rapamycin or inhibition of glutaminolysis abolished the discrepancy in tumorigenic capacity between SIRT4-depleted hepatoma cells and control cells. Suppression of LKB1 or promotion of AMP by metformin also abrogated the hyperproliferative phenotype caused by SIRT4 loss, which further confirmed that the LKB1/AMPKα/mTOR axis is required in SIRT4-deficiency-promoted HCC tumorigenesis. Conclusion: SIRT4 could exert its tumor suppressive function in HCC by inhibiting glutamine metabolism and thereby increasing the adenosine diphosphate (ADP)/AMP levels to phosphorylate AMPKα by LKB1, which blocks the mTOR signaling pathway.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Wang YS, Du L, Liang X, et al. Sirtuin 4 Depletion Promotes Hepatocellular Carcinoma Tumorigenesis Through Regulating Adenosine-Monophosphate-Activated Protein Kinase Alpha/Mammalian Target of Rapamycin Axis in Mice. Hepatology. 2019. PMID: 30552782. doi:10.1002/hep.30421

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。